ClinicalTrials.gg
CompletedNCT02045836Updated May 14, 2021Results posted

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

A Phase 3 interventional study of Herpes Zoster vaccine GSK 1437173A and Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ in Herpes Zoster and Herpes Zoster Vaccine, sponsored by GlaxoSmithKline. Completed at 9 sites in 3 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-14.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
865
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
12th of 46
865 · median 239
Started
2014
with 4 others
Phase 3
22 of 46
2 open now
Registered
12th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 12th largest by enrollment, is one of 5 that started in 2014, is one of 22 in phase 3, and was the 12th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on Pneumovax 23™ vaccine immune response will also be evaluated.

03

Conditions studied

  • Herpes Zoster
  • Herpes Zoster Vaccine

Browse trials for

Keywords

  • Pneumovax 23
  • Co-administration
  • Herpes zoster
  • Immunogenicity
  • Safety
  • Adults
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • A male or female aged 50 years or older at the time of the first vaccination with the study vaccine(s).
  • Written obtained from the subject.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of or other immune-modifying drugs within six months prior to the first vaccine dose. A prednisone dose of \< 20 mg/day is allowed. Inhaled, topical and intra-articular are allowed.
  • Administration or planned administration of a vaccine not foreseen by the study protocol within the period starting 30 days before the first dose of study vaccine(s) and ending 30 days after the last dose of study vaccine. This includes any type of vaccine such as live, inactivated and subunit vaccines.
  • Administration of long-acting immune-modifying drugs within six months prior to the first vaccine dose or expected administration at any time during the study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Previous vaccination against Varicella-zoster virus (VZV) or HZ and/or planned administration during the study of an HZ or VZV vaccine other than the study vaccine.
  • History of HZ.
  • History of documented pneumococcal infection within 5 previous years.
  • Prior receipt of any pneumococcal vaccine or planned use of this vaccine during the study period, other than the study vaccine.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy .
  • History of any reaction or likely to be exacerbated by any component of the vaccines.
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 37.5°C /99.5°F by oral route. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
  • Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions before 2 months after the last dose of study vaccine.
  • Any persons with cerebrospinal fluid (CSF) leaks, cochlear implants, chronic renal failure, nephrotic syndrome, and functional or anatomic asplenia.
  • Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.
  • Any condition which, in the judgment of the investigator, would make intramuscular (IM) injection unsafe.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
865 participants (actual)

Study arms

  • Experimental
    Co-Ad Group

    Subjects received one dose of the GSK1437173A study vaccine and one dose of the Pneumovax™ 23 vaccine at Day 0 and a second dose of GSK1437173A study vaccine at Month 2. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.

    Biological: Herpes Zoster vaccine GSK 1437173A · Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™

  • Active comparator
    Control Group

    Subjects received one dose of the Pneumovax™ 23 vaccine at Day 0, one dose of the GSK1437173A study vaccine at Month 2 and a second dose of the GSK1437173A study vaccine at Month 4. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.

    Biological: Herpes Zoster vaccine GSK 1437173A · Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With a Vaccine Response for Anti-gE Antibodies

    Vaccine response rate for anti-gE antibody concentrations, as determined by enzyme-linked immunosorbent assay (ELISA), in subjects from the Co-Ad group. Vaccine response defined as : For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL) For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration

    Time frame: At Month 3

  2. Anti-glicoprotein E (gE) Antibody Concentrations

    Antibody concentrations were determined by ELISA, presented as geometric mean concentrations and expressed as milli international units per milliliter (mIU/mL).

    Time frame: At one month post-dose 2 (Month 3 for the Co-Ad Group and Month 5 for the Control Group)

  3. Anti-pneumococcal Antibody Titers

    Anti-pneumococcal antibody titers were presented as geometric mean titers (GMTs) for the 12 following serotypes as determined by Opsonophagocytic Assay (OPA): 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

    Time frame: At one month post-dose (Month 1)

  4. Adjusted Ratios of Geometric Mean Titers (GMTs) Between Groups

    The Adjusted ratios of GMTs between groups (Control group and Co-Ad group) were presented for each individual pneumococcal conjugate serotype Opsonophagocytic Activity (OPA).

    Time frame: At 1 month after vaccination

  5. Adjusted GMCs Between Groups

    The Adjusted ratios of GMCs between groups (Control group and Co-Ad group) was presented for anti-gE antibody ELISA concentrations

    Time frame: At 1 month after last vaccine dose

Secondary outcomes

  1. Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Dose

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. The Co-Ad Group received only 2 vaccine doses.

    Time frame: Within 7 days (Days 0 - 6) after each vaccination

  2. Number of Subjects With Solicited Local Symptoms, Across Doses, by Vaccine

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: Within 7 days (Days 0 - 6) after vaccination

  3. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.

    Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  4. Number of Days With Any Solicited Local and General Symptoms

    The Co-Ad Group received only 2 vaccine doses, hence the number of participants for the Dose 3 categories in this group is 0.

    Time frame: Within 7 days (Days 0 - 6) after each vaccination

  5. Number of Subjects With Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: From the first dose up to 30 days post last vaccination period

  6. Number of Subjects With Serious Adverse Events (SAEs) [From the First Dose up to 30 Days Post Last Vaccination Period]

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From the first dose up to 30 days post last vaccination period

  7. Number of Subjects With Serious Adverse Events (SAEs) [From 30 Days Post Last Vaccination up to Study End]

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From 30 days post last vaccination up to study end

  8. Number of Subjects With Potential Immune Mediated Diseases (pIMDs) [From First Vaccination up to 30 Days Post Last Vaccination]

    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: From first vaccination up to 30 days post last vaccination (Month 0 - Month 3 for the Co-Ad Group & Month 0 - Month 5 for the Control Group)

  9. Number of Subjects With Potential Immune Mediated Diseases (pIMDs) [During the Period Starting After 30 Days Post Last Vaccination up to Study End]

    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

    Time frame: During the period starting after 30 days post last vaccination up to study end (Month 3 - Month 14 for the Co-Ad Group & Month 5 - Month 16 for the Control Group)

07

Results

Posted Jul 5, 2017

Participant flow

Participant flow — Overall Study
MilestoneCo-Ad GroupControl Group
Started432433
Completed423419
Not completed914
Withdrew: Adverse event44
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow-up47
Withdrew: Migrated from study area02

Outcome measures

PrimaryNumber of Subjects With a Vaccine Response for Anti-gE Antibodies

Vaccine response rate for anti-gE antibody concentrations, as determined by enzyme-linked immunosorbent assay (ELISA), in subjects from the Co-Ad group. Vaccine response defined as : For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL) For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration

Time frame:
At Month 3
Reported as:
Count of participants · Participants
Number of Subjects With a Vaccine Response for Anti-gE Antibodies
ParticipantsCo-Ad Group
Number of Subjects With a Vaccine Response for Anti-gE Antibodies394
PrimaryAnti-glicoprotein E (gE) Antibody Concentrations

Antibody concentrations were determined by ELISA, presented as geometric mean concentrations and expressed as milli international units per milliliter (mIU/mL).

Time frame:
At one month post-dose 2 (Month 3 for the Co-Ad Group and Month 5 for the Control Group)
Reported as:
Geometric mean · mIU/mL
Anti-glicoprotein E (gE) Antibody Concentrations
mIU/mLCo-Ad GroupControl Group
Anti-glicoprotein E (gE) Antibody Concentrations49918.0 (47143.0 to 52856.3)50327.9 (47200.4 to 53662.7)
PrimaryAnti-pneumococcal Antibody Titers

Anti-pneumococcal antibody titers were presented as geometric mean titers (GMTs) for the 12 following serotypes as determined by Opsonophagocytic Assay (OPA): 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

Time frame:
At one month post-dose (Month 1)
Reported as:
Geometric mean · Titers
Anti-pneumococcal Antibody Titers
TitersCo-Ad GroupControl Group
MOPA-165.1 (54.2 to 78.1)68.6 (56.9 to 82.7)
MOPA-9V1898.4 (1618.1 to 2227.2)1991.3 (1716.0 to 2310.8)
MOPA-142629.4 (2297.4 to 3009.3)2612.8 (2230.7 to 3060.3)
MOPA-3106.7 (92.6 to 122.9)107.4 (92.7 to 124.4)
MOPA-41079.4 (924.0 to 1260.9)1328.8 (1141.0 to 1547.6)
MOPA-5161.4 (134.6 to 193.6)149.5 (123.5 to 181.0)
MOPA-6B1619.0 (1354.5 to 1935.0)1564.4 (1303.5 to 1877.6)
MOPA-7F2352.5 (2049.5 to 2700.3)2460.4 (2128.7 to 2843.8)
MOPA-18C1077.4 (921.1 to 1260.2)1076.0 (918.2 to 1260.9)
MOPA-19A1349.6 (1152.1 to 1580.8)1573.1 (1350.7 to 1832.2)
MOPA-19F904.3 (779.6 to 1049.0)953.0 (814.8 to 1114.6)
MOPA-23F431.4 (356.1 to 522.7)367.3 (300.8 to 448.5)
PrimaryAdjusted Ratios of Geometric Mean Titers (GMTs) Between Groups

The Adjusted ratios of GMTs between groups (Control group and Co-Ad group) were presented for each individual pneumococcal conjugate serotype Opsonophagocytic Activity (OPA).

Time frame:
At 1 month after vaccination
Reported as:
Geometric mean · Titers
Adjusted Ratios of Geometric Mean Titers (GMTs) Between Groups
TitersCo-Ad GroupControl Group
MOPA-167.6 (56.9 to 80.2)65.6 (55.2 to 77.9)
MOPA-3105.0 (92.2 to 119.5)108.9 (95.7 to 124.1)
MOPA-41264.1 (1089.9 to 1466.2)1117.2 (963.1 to 1296.1)
MOPA-5152.6 (129.1 to 180.3)159.8 (135.1 to 188.9)
MOPA-6B1536.8 (1307.9 to 1805.7)1666.6 (1418.0 to 1958.6)
MOPA-7F2491.3 (2179.8 to 2847.5)2324.7 (2033.3 to 2657.9)
MOPA-9V1911.8 (1651.6 to 2212.9)1970.3 (1700.9 to 2282.3)
MOPA-142610.1 (2281.6 to 2986.0)2678.1 (2339.4 to 3065.8)
MOPA-18C1040.9 (902.7 to 1200.4)1099.8 (952.8 to 1269.6)
MOPA-19A1558.6 (1361.8 to 1783.8)1350.5 (1180.0 to 1545.7)
MOPA-19F938.2 (814.6 to 1080.7)914.1 (793.4 to 1053.3)
MOPA-23F372.8 (316.0 to 439.8)419.1 (354.9 to 494.9)
Statistical analysis
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmt: 1.03 · 95% CI 0.81 to 1.31Adjusted GMT ratio (Control group / Co-Ad group)
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmt: 0.96 · 95% CI 0.8 to 1.16Adjusted GMT ratio (Control group / Co-Ad group)
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmt: 1.13 · 95% CI 0.92 to 1.4Adjusted GMT ratio (Control group / Co-Ad group)
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmt: 0.96 · 95% CI 0.75 to 1.21Adjusted GMT ratio (Control group / Co-Ad group)
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmt: 0.92 · 95% CI 0.73 to 1.16Adjusted GMT ratio (Control group / Co-Ad group)
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmt: 1.07 · 95% CI 0.89 to 1.29Adjusted GMT ratio (Control group / Co-Ad group)
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmt: 0.97 · 95% CI 0.79 to 1.19Adjusted GMT ratio (Control group / Co-Ad group)
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmt: 0.97 · 95% CI 0.81 to 1.18Adjusted GMT ratio (Control group / Co-Ad group)
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmt: 0.95 · 95% CI 0.77 to 1.16Adjusted GMT ratio (Control group / Co-Ad group)
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmt: 1.15 · 95% CI 0.95 to 1.4Adjusted GMT ratio (Control group / Co-Ad group)
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmt: 1.03 · 95% CI 0.84 to 1.25Adjusted GMT ratio (Control group / Co-Ad group)
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmt: 0.89 · 95% CI 0.7 to 1.12Adjusted GMT ratio (Control group / Co-Ad group)
PrimaryAdjusted GMCs Between Groups

The Adjusted ratios of GMCs between groups (Control group and Co-Ad group) was presented for anti-gE antibody ELISA concentrations

Time frame:
At 1 month after last vaccine dose
Reported as:
Geometric mean · mIU/mL
Adjusted GMCs Between Groups
mIU/mLCo-Ad GroupControl Group
Adjusted GMCs Between Groups49569.0 (46641.4 to 52680.4)50474.5 (47497.4 to 53638.2)
Statistical analysis
  • Co-Ad Group vs Control Group · ANCOVA · Adjusted gmc: 1.02 · 95% CI 0.93 to 1.11Adjusted ratios of GMCs between groups (Control group and Co-Ad group)
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms, by Dose

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. The Co-Ad Group received only 2 vaccine doses.

Time frame:
Within 7 days (Days 0 - 6) after each vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Dose
ParticipantsCo-Ad GroupControl Group
Any Pain, Dose 1344169
Grade 3 Pain, Dose 1465
Any Redness, Dose 118231
Grade 3 Redness, Dose 1152
Any Swelling, Dose 19921
Grade 3 Swelling, Dose 141
Any Pain, Dose 2298290
Grade 3 Pain, Dose 23528
Any Redness, Dose 2146129
Grade 3 Redness, Dose 2154
Any Swelling, Dose 27967
Grade 3 Swelling, Dose 242
Any Pain, Dose 30293
Grade 3 Pain, Dose 3032
Any Redness, Dose 30136
Grade 3 Redness, Dose 308
Any Swelling, Dose 3074
Grade 3 Swelling, Dose 303
Any Pain, Across Doses372357
Grade 3 Pain, Across Doses6849
Any Redness, Across Doses233194
Grade 3 Redness, Across Doses2712
Any Swelling, Across Doses137115
Grade 3 Swelling, Across Doses76
SecondaryNumber of Subjects With Solicited Local Symptoms, Across Doses, by Vaccine

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
Within 7 days (Days 0 - 6) after vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Symptoms, Across Doses, by Vaccine
ParticipantsCo-Ad GroupControl Group
Any Pain, GSK1437173A, Across Doses369343
Any Pain, Pneumovax 23, Across Doses223169
Any Redness, GSK1437173A, Across Doses223186
Any Redness, Pneumovax 23, Across Doses6931
Any Swelling, GSK1437173A, Across Doses129108
Any Swelling, Pneumovax 23, Across Doses3621
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms.

Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, myalgia, shivering and sweating. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.
ParticipantsCo-Ad GroupControl Group
Any Fatigue, Dose 119487
Grade 3 Fatigue, Dose 1273
Related Fatigue, Dose 117581
Any Gastrointestinal symptoms, Dose 17631
Grade 3 Gastrointestinal symptoms, Dose 161
Related Gastrointestinal symptoms, Dose 16728
Any Headache, Dose 115672
Grade 3 Headache, Dose 1153
Related Headache, Dose 114164
Any Myalgia, Dose 118787
Grade 3 Myalgia, Dose 1295
Related Myalgia, Dose 117782
Any Shivering, Dose 19127
Grade 3 Shivering, Dose 1121
Related Shivering, Dose 18626
Any Temperature, Dose 16912
Grade 3 Temperature, Dose 111
Related Temperature, Dose 16711
Any Fatigue, Dose 2191124
Grade 3 Fatigue, Dose 22911
Related Fatigue, Dose 2174109
Any Gastrointestinal symptoms, Dose 26138
Grade 3 Gastrointestinal symptoms, Dose 264
Related Gastrointestinal symptoms, Dose 25229
Any Headache, Dose 2141104
Grade 3 Headache, Dose 2199
Related Headache, Dose 212485
Any Myalgia, Dose 2182124
Grade 3 Myalgia, Dose 22511
Related Myalgia, Dose 2171119
Any Shivering, Dose 28330
Grade 3 Shivering, Dose 2143
Related Shivering, Dose 27825
Any Temperature, Dose 26730
Grade 3 Temperature, Dose 200
Related Temperature, Dose 26326
Any Fatigue, Dose 30174
Grade 3 Fatigue, Dose 3022
Related Fatigue, Dose 30166
Any Gastrointestinal symptoms, Dose 3047
Grade 3 Gastrointestinal symptoms, Dose 303
Related Gastrointestinal symptoms, Dose 3046
Any Headache, Dose 30144
Grade 3 Headache, Dose 3013
Related Headache, Dose 30135
Any Myalgia, Dose 30162
Grade 3 Myalgia, Dose 3026
Related Myalgia, Dose 30157
Any Shivering, Dose 3072
Grade 3 Shivering, Dose 3011
Related Shivering, Dose 3069
Any Temperature, Dose 3067
Grade 3 Temperature, Dose 302
Related Temperature, Dose 3066
Any Fatigue, Across doses253228
Grade 3 Fatigue, Across doses4731
Related Fatigue, Across doses236216
Any Gastrointestinal symptoms, Across doses11484
Grade 3 Gastrointestinal symptoms, Across doses127
Related Gastrointestinal symptoms, Across doses10077
Any Headache, Across doses209208
Grade 3 Headache, Across doses2924
Related Headache, Across doses195193
Any Myalgia, Across doses257225
Grade 3 Myalgia, Across doses4637
Related Myalgia, Across doses245218
Any Shivering, Across doses13799
Grade 3 Shivering, Across doses2515
Related Shivering, Across doses13195
Any Temperature, Across doses11296
Grade 3 Temperature, Across doses13
Related Temperature, Across doses10891
SecondaryNumber of Days With Any Solicited Local and General Symptoms

The Co-Ad Group received only 2 vaccine doses, hence the number of participants for the Dose 3 categories in this group is 0.

Time frame:
Within 7 days (Days 0 - 6) after each vaccination
Reported as:
Median · days
Number of Days With Any Solicited Local and General Symptoms
daysCo-Ad GroupControl Group
Any Pain, Dose 13 (2 to 4)2 (1 to 3)
Any Pain, Dose 23 (2 to 4)3 (2 to 4)
Any Pain, Dose 3—3 (2 to 4)
Any Redness, Dose 13 (2 to 5)2 (1 to 3)
Any Redness, Dose 23 (2 to 4)3 (2 to 5)
Any Redness, Dose 3—3 (2 to 4)
Any Swelling, Dose 13 (2 to 5)2 (1 to 3)
Any Swelling, Dose 23 (2 to 4)4 (2 to 5)
Any Swelling, Dose 3—3 (2 to 5)
Any Fatigue, Dose 12 (1 to 4)2 (1 to 4)
Any Fatigue, Dose 22 (1 to 3)2 (1 to 3)
Any Fatigue, Dose 3—2 (1 to 3)
Any Gastrointestinal, Dose 12 (1 to 2.5)2 (1 to 3)
Any Gastrointestinal, Dose 22 (1 to 3)2 (1 to 3)
Any Gastrointestinal, Dose 3—2 (1 to 2)
Any Headache, Dose 12 (1 to 3)2 (1 to 2)
Any Headache, Dose 22 (1 to 3)2 (1 to 2.5)
Any Headache, Dose 3—2 (1 to 2)
Any Myalgia, Dose 12 (2 to 4)2 (1 to 3)
Any Myalgia, Dose 22 (1 to 3)2 (1 to 3.5)
Any Myalgia, Dose 3—2 (2 to 3)
Any Shivering, Dose 11 (1 to 2)2 (1 to 2)
Any Shivering, Dose 21 (1 to 2)1 (1 to 2)
Any Shivering, Dose 3—1 (1 to 2)
Any Temperature (Oral), Dose 11 (1 to 2)1 (1 to 2)
Any Temperature (Oral), Dose 21 (1 to 2)1 (1 to 2)
Any Temperature (Oral), Dose 3—1 (1 to 2)
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
From the first dose up to 30 days post last vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Adverse Events (AEs)
ParticipantsCo-Ad GroupControl Group
Subjects with any AE(s)132140
Subjects with grade 3 AE(s)1628
Subjects with related AE(s)3428
SecondaryNumber of Subjects With Serious Adverse Events (SAEs) [From the First Dose up to 30 Days Post Last Vaccination Period]

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From the first dose up to 30 days post last vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs) [From the First Dose up to 30 Days Post Last Vaccination Period]
ParticipantsCo-Ad GroupControl Group
Subjects with any SAE(s)79
Fatal SAEs00
SecondaryNumber of Subjects With Serious Adverse Events (SAEs) [From 30 Days Post Last Vaccination up to Study End]

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From 30 days post last vaccination up to study end
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs) [From 30 Days Post Last Vaccination up to Study End]
ParticipantsCo-Ad GroupControl Group
Subjects with any SAE(s)1010
Fatal SAE(s)22
Related SAE(s)22
SecondaryNumber of Subjects With Potential Immune Mediated Diseases (pIMDs) [From First Vaccination up to 30 Days Post Last Vaccination]

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
From first vaccination up to 30 days post last vaccination (Month 0 - Month 3 for the Co-Ad Group & Month 0 - Month 5 for the Control Group)
Reported as:
Count of participants · Participants
Number of Subjects With Potential Immune Mediated Diseases (pIMDs) [From First Vaccination up to 30 Days Post Last Vaccination]
ParticipantsCo-Ad GroupControl Group
Any pIMDs01
Related pIMDs00
SecondaryNumber of Subjects With Potential Immune Mediated Diseases (pIMDs) [During the Period Starting After 30 Days Post Last Vaccination up to Study End]

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Time frame:
During the period starting after 30 days post last vaccination up to study end (Month 3 - Month 14 for the Co-Ad Group & Month 5 - Month 16 for the Control Group)
Reported as:
Count of participants · Participants
Number of Subjects With Potential Immune Mediated Diseases (pIMDs) [During the Period Starting After 30 Days Post Last Vaccination up to Study End]
ParticipantsCo-Ad GroupControl Group
Number of Subjects With Potential Immune Mediated Diseases (pIMDs) [During the Period Starting After 30 Days Post Last Vaccination up to Study End]10

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Co-Ad Group2/432 (0.5%)17/432 (3.9%)400/432 (92.6%)
Control Group5/433 (1.2%)19/433 (4.4%)393/433 (90.8%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventCo-Ad GroupControl Group
Acute myocardial infarctionCardiac disorders3/4321/433
PneumoniaInfections and infestations1/4323/433
Atrial fibrillationCardiac disorders2/4321/433
Cardiac failure congestiveCardiac disorders1/4322/433
Chest painGeneral disorders0/4322/433
Cerebral infarctionNervous system disorders0/4322/433
TachycardiaCardiac disorders1/4320/433
Gastric ulcerGastrointestinal disorders1/4320/433
AstheniaGeneral disorders1/4320/433
SarcoidosisImmune system disorders1/4320/433
Most frequent other events
Most frequent other events
EventCo-Ad GroupControl Group
PainGeneral disorders372/432357/433
MyalgiaMusculoskeletal and connective tissue disorders257/432227/433
FatigueGeneral disorders253/432228/433
ErythemaGeneral disorders234/432194/433
HeadacheNervous system disorders210/432209/433
ChillsGastrointestinal disorders137/43299/433
SwellingGeneral disorders137/432115/433
Gastrointestinal disorderGastrointestinal disorders114/43284/433
PyrexiaGeneral disorders112/43297/433

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Co-Ad GroupControl GroupTotal
Mean63.2 ± 8.463.2 ± 8.463.2 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Co-Ad GroupControl GroupTotal
Female264252516
Male168181349
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Co-Ad GroupControl GroupTotal
White - Caucasian / European Heritage408406814
African Heritage / African American12921
American Indian or Alaskan Native134
Asian - East Asian Heritage3710
Asian - Japanese Heritage011
Asian - South East Asian Heritage426
White - Arabic / North African Heritage202
Mixed Origin257
08

Study locations

9 sites
  • GSK Investigational Site
    Golden, Colorado 80401, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Columbia, Maryland 21045, United States
  • GSK Investigational Site
    Coquitlam, British Columbia V3K 3P4, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    Sudbury, Ontario P3E 1H5, Canada
  • GSK Investigational Site
    Tallinn, 10117, Estonia
  • GSK Investigational Site
    Tallinn, 13619, Estonia
  • GSK Investigational Site
    Tartu, 50106, Estonia
09

References and documents

Publications

  • Marechal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC, Herve C, Rheault P, Talli J, Wauters D, Oostvogels L. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults >/=50 years of age: A randomized trial. Vaccine. 2018 Jul 5;36(29):4278-4286. doi: 10.1016/j.vaccine.2018.05.110. Epub 2018 Jun 11. Erratum In: Vaccine. 2019 Feb 21;37(9):1252-1253. doi: 10.1016/j.vaccine.2019.01.022. PubMed 29903674 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jul 2015, 15 months.

Results were first posted in Jul 2017, 2 years after primary completion. A results delay was requested in Nov 2015.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 15 months is close to that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2014
First posted
Jan 27, 2014
StartActual
Mar 5, 2014
Primary completionActual
Jul 2, 2015
CompletionActual
Jun 17, 2016
Results delay requested
Nov 12, 2015
Results first posted
Jul 5, 2017
Last update
May 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02045836
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 27, 2014
Start date
Mar 5, 2014
Primary completion
Jul 2, 2015
Completion
Jun 17, 2016
Results posted
Jul 5, 2017
Last update
May 14, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion